Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
Matthew W McClureElina BerlibaTengiz TsertsvadzeAdrian Streinu-CercelLeen VijgenBéatrice AstrucAlain PatatChristopher WestlandSushmita ChandaQingling ZhangThomas N KakudaJennifer VuongNick KhorlinLeonid BeigelmanLawrence M BlattJohn FryPublished in: PloS one (2018)
AL-335 was well tolerated when administered as single and multiple doses, with an acceptable pharmacokinetic profile. The drug also demonstrated potent antiviral activity in HCV GT1-4-infected subjects, including GT1-infected subjects with cirrhosis.